In 2013, ADCs achieved another breakthrough with the approval of Trastuzumab emtansine (TDM‐1) by the US FDA for human epidermal growth factor receptor‐2 (HER2)‐positive breast cancer.7 This evidence concerns the gene ERBB2 and breast carcinoma.